<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0379-3982</journal-id>
<journal-title><![CDATA[Revista Tecnología en Marcha]]></journal-title>
<abbrev-journal-title><![CDATA[Tecnología en Marcha]]></abbrev-journal-title>
<issn>0379-3982</issn>
<publisher>
<publisher-name><![CDATA[Instituto Tecnológico de Costa Rica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0379-39822022000300016</article-id>
<article-id pub-id-type="doi">10.18845/tm.v35i3.5612</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Inmunoterapia activa con anticuerpos monoclonales como opción terapéutica para el tratamiento del cáncer de páncreas]]></article-title>
<article-title xml:lang="en"><![CDATA[Active immunotherapy with monoclonal antibodies as a therapeutic option for the treatment of pancreatic cancer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barquero-Solano]]></surname>
<given-names><![CDATA[Arisai]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guevara-Saborío]]></surname>
<given-names><![CDATA[Gloriana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montero-Rivera]]></surname>
<given-names><![CDATA[Jeison]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vargas-Sandoval]]></surname>
<given-names><![CDATA[Lázaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Velásquez-Alfaro]]></surname>
<given-names><![CDATA[Luis Daniel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mora-Román]]></surname>
<given-names><![CDATA[Juan José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Costa Rica Facultad de Farmacia ]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Costa Rica Facultad de Farmacia ]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Costa Rica Facultad de Farmacia ]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad de Costa Rica Facultad de Farmacia ]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Universidad de Costa Rica Facultad de Farmacia ]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Universidad de Costa Rica Departamento de Farmacia Industrial Facultad de Farmacia]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<volume>35</volume>
<numero>3</numero>
<fpage>16</fpage>
<lpage>34</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S0379-39822022000300016&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S0379-39822022000300016&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S0379-39822022000300016&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El cáncer de páncreas es el sexto más mortal a nivel mundial, y en el caso específico de Costa Rica el sétimo en importancia. La gran problemática asociada a esta patología es un diagnóstico en etapas avanzadas, ya que sus síntomas son muy inespecíficos y en muchos casos no se presentan. Abonado a lo anterior, el tratamiento por excelencia es la cirugía, mas no resulta ser del todo alentadora, pues la mayoría de pacientes no pueden ser operados, y aunque se utilice quimioterapia y radioterapia, la supervivencia de vida a los cinco años es sumamente baja. Por eso, se han investigado nuevas opciones terapéuticas, incluidas las biológicas. Dentro de ellas, se encuentran los anticuerpos monoclonales, cuyo mecanismo de acción implica una inmunoterapia activa. En este momento, se encuentran en fase de investigación a través de estudios clínicos de fases I y II. Gran parte se está evaluando en combinación con otros fármacos. Los resultados sobre estos estudios son escasos, pero se espera a futuro disponer de mayor información, junto con un número creciente de opciones que permitan en el mediano plazo su disponibilidad como alternativas terapéuticas para mejorar la esperanza y la calidad de vida de las personas que padecen esta enfermedad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Pancreatic cancer is the sixth most deadly worldwide, and in the specific case of Costa Rica, the seventh in importance. The significant problem associated with this pathology is a diagnosis in advanced stages since its symptoms are very nonspecific, and in many cases, they do not appear. Also, the treatment per excellence is surgery, but it does not turn out to be entirely encouraging since most patients cannot underwent surgery on, and although chemotherapy and radiotherapy are used, life survival at five years is extremely low. For this reason, new therapeutic options, including biological ones, have been investigated. Among them are monoclonal antibodies, whose mechanism of action involves active immunotherapy. At this time, they are in the research stage through phase I and II clinical studies. Most are being evaluated in combination with other drugs. The results of these investigations are scarce, but it is expected in the future to have more information, together with a growing number of options that will allow their availability in the medium term as therapeutic alternatives to improve the hope and quality of life of the people who suffer from this sickness.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cáncer de pancreas]]></kwd>
<kwd lng="es"><![CDATA[tratamiento]]></kwd>
<kwd lng="es"><![CDATA[anticuerpos monoclonales]]></kwd>
<kwd lng="es"><![CDATA[inmunoterapia activa]]></kwd>
<kwd lng="es"><![CDATA[punto de control inmunitario]]></kwd>
<kwd lng="en"><![CDATA[Pancreatic cancer]]></kwd>
<kwd lng="en"><![CDATA[treatment]]></kwd>
<kwd lng="en"><![CDATA[monoclonal antibodies]]></kwd>
<kwd lng="en"><![CDATA[active immunotherapy]]></kwd>
<kwd lng="en"><![CDATA[immune checkpoint]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boticario Boticario]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cascales Angosto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Innovaciones en Cáncer]]></article-title>
<source><![CDATA[]]></source>
<year>2008</year>
<publisher-loc><![CDATA[San José, Costa Rica ]]></publisher-loc>
<publisher-name><![CDATA[UNED]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iglesias-García]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Lariño Noia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez Muñoz]]></surname>
<given-names><![CDATA[J. E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de páncreas]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2012</year>
<volume>11</volume>
<page-range>473-80</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kleeff]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Korc]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Apte]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vecchia]]></surname>
<given-names><![CDATA[C. La]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[C. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Biankin]]></surname>
<given-names><![CDATA[A. V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pancreatic cancer]]></article-title>
<source><![CDATA[Nature Reviews Disease Primers]]></source>
<year>2016</year>
<volume>2</volume>
<page-range>16022</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez Gordo]]></surname>
<given-names><![CDATA[A. M.]]></given-names>
</name>
<name>
<surname><![CDATA[López Gómez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Casado]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización en cáncer de páncreas y de vías biliares]]></article-title>
<source><![CDATA[Medicine,]]></source>
<year>2017</year>
<volume>12</volume>
<page-range>1919-28</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conroy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hammel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hebbar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ben]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Abdelghani]]></surname>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[A. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Raoul]]></surname>
<given-names><![CDATA[J. L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer,'']]></article-title>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>2018</year>
<volume>379</volume>
<page-range>2395-406</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elnemr]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sultan]]></surname>
<given-names><![CDATA[A. A. E. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Nassar]]></surname>
<given-names><![CDATA[S. M. S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent Advances and Surgical Applications of Monoclonal Antibodies,]]></article-title>
<source><![CDATA[The Egyptian Journal of Hospital Medicine]]></source>
<year>2019</year>
<volume>77</volume>
<page-range>5668-78</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dougan]]></surname>
<given-names><![CDATA[S. K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Pancreatic Cancer Microenvironment]]></article-title>
<source><![CDATA[The Cancer Journal]]></source>
<year>2017</year>
<volume>23</volume>
<page-range>321-5</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Collisson]]></surname>
<given-names><![CDATA[E. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Sadanandam]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Olson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gibb]]></surname>
<given-names><![CDATA[W. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Truitt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy]]></article-title>
<source><![CDATA[Nature Medicine]]></source>
<year>2011</year>
<volume>17</volume>
<page-range>500-3</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Naqvi]]></surname>
<given-names><![CDATA[A. A. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Hasan]]></surname>
<given-names><![CDATA[G. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Hassan]]></surname>
<given-names><![CDATA[M. I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Investigating the role of transcription factors of pancreas development in pancreatic cancer]]></article-title>
<source><![CDATA[Pancreatology]]></source>
<year>2018</year>
<volume>18</volume>
<page-range>184-90</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="">
<collab>Sociedad Americana de Oncología Clínica</collab>
<source><![CDATA[Cáncer de páncreas: Estadios]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Batista]]></surname>
<given-names><![CDATA[I. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Melo]]></surname>
<given-names><![CDATA[S. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exosomes and the Future of Immunotherapy in Pancreatic Cancer]]></article-title>
<source><![CDATA[International Journal of Molecular Science]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>567</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz Martín]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Prieto Martín]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Monserrat Sanz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Luengo]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez-Mon Soto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sistema inmune y cáncer]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2009</year>
<volume>10</volume>
<page-range>1900-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lizarazo Rodríguez]]></surname>
<given-names><![CDATA[J. I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patogénesis del cáncer de páncreas,]]></article-title>
<source><![CDATA[Revista Colombiana de Gastroenterología]]></source>
<year>2008</year>
<volume>23</volume>
<page-range>391-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asati]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mahapatra]]></surname>
<given-names><![CDATA[D. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Bharti]]></surname>
<given-names><![CDATA[S. K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives]]></article-title>
<source><![CDATA[European Journal of Medicinal Chemistry]]></source>
<year>2017</year>
<volume>125</volume>
<page-range>299</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kopp]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The proto-oncogene KRAS is targeted by miR-200c]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Roidl]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncotarget]]></source>
<year>2014</year>
<volume>. 5</volume>
<page-range>185-95</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carvallo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Conceptos sobre Genética Humana para la Comprensión e Interpretación de las Mutaciones en Cáncer y otras Patologías Hereditarias]]></article-title>
<source><![CDATA[Revista Médica Clínica Las Condes]]></source>
<year>2017</year>
<volume>28</volume>
<page-range>531-7</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roser]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ritchie]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[R. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[K. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer Statistics, 2020]]></article-title>
<source><![CDATA[Cancer Journal for Clinicians]]></source>
<year>2020</year>
<volume>70</volume>
<page-range>7-30</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caglevic]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gallardo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[de la Torre]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mahave]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Muller]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Solé]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recomendaciones sobre el manejo del cáncer de páncreas tipo adenocarcinoma en Latinoamérica: Reunión del Consenso del Simposio Latinoamericano de Gastroenterología Oncológica (SLAGO) y de la Asociación Ibero Latinoamericana de Terapia Radiante (ALATRO), Viña del Mar, Chile 2015]]></article-title>
<source><![CDATA[Revista Médica de Chile]]></source>
<year>2016</year>
<volume>144</volume>
<page-range>1305-18</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chielle]]></surname>
<given-names><![CDATA[E. O.]]></given-names>
</name>
<name>
<surname><![CDATA[Kuiava]]></surname>
<given-names><![CDATA[V. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiologia do Câncer de Pâncreas na Região Sul do Brasil: Estudo da Base de Dados do Departamento de Informática do Sistema Único de Saúde (Datasus),'']]></article-title>
<source><![CDATA[Revista de Atençao à Saúde]]></source>
<year>2018</year>
<volume>16</volume>
<page-range>32-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bosetti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bertuccio]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Negri]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Vecchia]]></surname>
<given-names><![CDATA[C. La]]></given-names>
</name>
<name>
<surname><![CDATA[Zeegers]]></surname>
<given-names><![CDATA[M. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Boffetta]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pancreatic Cancer: Overview of Descriptive Epidemiology]]></article-title>
<source><![CDATA[Molecular Carcinogenesis]]></source>
<year>2012</year>
<volume>51</volume>
<page-range>3-13</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="">
<collab>Ministerio de Salud de Costa Rica</collab>
<source><![CDATA[https://www.ministeriodesalud.go.cr/index.php/vigilancia-de-la-salud/estadisticas-y-bases-de-datos/estadisticas/estadistica-de-cancer-registro-nacional-tumores/incidencia]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<collab>Ministerio de Salud de Costa Rica.</collab>
<article-title xml:lang=""><![CDATA[Mortalidad por Tumores Malignos más Frecuentes en Mujeres y en Hombres por Cantón]]></article-title>
<source><![CDATA[https://www.ministeriodesalud.go.cr/index.php/vigilanciade-la-salud/estadisticas-y-bases-de-datos/estadisticas/estadistica-de-cancer-registro-nacional-tumores/mortalidad]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López Penza]]></surname>
<given-names><![CDATA[P. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ruso Martínez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de páncreas: Epidemiología de su mal pronóstico]]></article-title>
<source><![CDATA[Revista Médica del Uruguay]]></source>
<year>2017</year>
<volume>33</volume>
<page-range>180-6</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López Serrano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores de riesgo y diagnóstico temprano del cáncer de páncreas]]></article-title>
<source><![CDATA[Gastroenterology &amp; Hepatology]]></source>
<year>2010</year>
<volume>33</volume>
<page-range>382-90</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pacheco Mejías]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de páncreas, un reto al sistema sanitario]]></article-title>
<source><![CDATA[Revista Archivo Médico de Camaguey]]></source>
<year>2018</year>
<volume>22</volume>
<page-range>847-76</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hermida Lazcano]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Tejero]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nerín Sánchez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cordero Bernabé]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mora Escudero]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Pinar Sánchez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Marcadores Tumorales]]></article-title>
<source><![CDATA[Revista Clínica Médica Familiar]]></source>
<year>2016</year>
<volume>9</volume>
<page-range>31-42</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campuzano Maya]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilidad clínica de los marcadores tumorales,]]></article-title>
<source><![CDATA[Medicina &amp; Laboratorio]]></source>
<year>2010</year>
<volume>16</volume>
<page-range>411-45</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aragón Sánchez]]></surname>
<given-names><![CDATA[J. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Macias]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rico Morlan]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Barra Martínez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Rodríguez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[de la Garza]]></surname>
<given-names><![CDATA[J. M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Niveles séricos de CA 19-9 como predictor de la resecabilidad quirúrgica en adenocarcinoma de páncreas]]></article-title>
<source><![CDATA[Gaceta Mexicana de Oncología,]]></source>
<year>2007</year>
<volume>6,</volume>
<page-range>59-64</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jans]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Talma]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Almonacid]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cáceres]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenfeld]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rendimiento diagnóstico del marcador tumoral CA 19-9 en la diferenciación entre patología bilio-pancreática beninga y maligna]]></article-title>
<source><![CDATA[Revista Chilena de Cirugía]]></source>
<year>2013</year>
<volume>65</volume>
<page-range>307-14</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Santibañes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mazza]]></surname>
<given-names><![CDATA[O. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Manejo actual del cáncer de páncreas]]></article-title>
<source><![CDATA[Revista del Hospital Italiano de Buenos Aires]]></source>
<year>2013</year>
<volume>33</volume>
<page-range>13-7</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez Cabús]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Cruz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cirugía del cáncer de páncreas: estrategias quirúrgicas según los datos basados en la evidencia]]></article-title>
<source><![CDATA[Cirugía Española]]></source>
<year>2015</year>
<volume>93</volume>
<page-range>432</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Busquets]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fabregat]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jorba]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Peláez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[García-Borobia]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Masuet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento quirúrgico del adenocarcinoma pancreático mediante duodenopancreatectomía cefálica (Parte 1): Complicaciones postoperatorias en 204 casos en un centro de referencia]]></article-title>
<source><![CDATA[Cirugía Española,]]></source>
<year>2010</year>
<volume>88</volume>
<page-range>299</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fabregat]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Busquets]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Peláez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Jorba]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[García-Borobia]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Masuet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento quirúrgico del adenocarcinoma pancreático mediante duodenopancreatectomía cefálica (Parte 2): Seguimiento a largo plazo tras 204 casos,]]></article-title>
<source><![CDATA[Cirugía Española]]></source>
<year>2010</year>
<volume>88</volume>
<page-range>374-82</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buc]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sauvanet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Duodenopancreatectomía cefálica]]></article-title>
<source><![CDATA[EMC - Técnicas Quirúrgicas - Aparato Digestivo]]></source>
<year>2012</year>
<volume>28</volume>
<page-range>1-25</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<collab>National Comprehensive Cancer Network</collab>
<article-title xml:lang=""><![CDATA[NCCN Guidelines for Patients: Pancreatic Cancer]]></article-title>
<source><![CDATA[National Comprehensive Cancer Network]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Pensilvania, Estados Unidos ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="">
<collab>Wolters Kluwer</collab>
<source><![CDATA[UpToDate]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<collab>Instituto Nacional del Cáncer</collab>
<article-title xml:lang=""><![CDATA[Imunoterapia para tratar el cáncer]]></article-title>
<source><![CDATA[https://www. cancer.gov/espanol/cancer/tratamiento/tipos/inmunoterapia]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alonso Castellanos]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Soto Célix]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso Galarreta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[del Riego Valledor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Miján de la Torre]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectos adversos metabólicos y nutricionales asociados a la terapia biológica del cáncer,]]></article-title>
<source><![CDATA[Nutrición Hospitalaria]]></source>
<year>2014</year>
<volume>29</volume>
<page-range>259-68</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Ramos]]></surname>
<given-names><![CDATA[S. E.]]></given-names>
</name>
<name>
<surname><![CDATA[García Poza]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilización terapéutica de los anticuerpos monoclonales]]></article-title>
<source><![CDATA[Ars Pharmaceutica]]></source>
<year>2011</year>
<volume>52</volume>
<page-range>46-57</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dimitrov]]></surname>
<given-names><![CDATA[J. D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Harnessing the Therapeutic Potential of 'Rogue' Antibodies,]]></article-title>
<source><![CDATA[Trends in Pharmacological Sciences]]></source>
<year>2020</year>
<volume>41</volume>
<page-range>409</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[N. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Tellez]]></surname>
<given-names><![CDATA[G. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Castaño]]></surname>
<given-names><![CDATA[J. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticuerpos monoclonales: desarrollo físico y perspectivas terapéuticas]]></article-title>
<source><![CDATA[Infectio]]></source>
<year>2006</year>
<volume>10</volume>
<page-range>186-97</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parray]]></surname>
<given-names><![CDATA[H. A]]></given-names>
</name>
<name>
<surname><![CDATA[Shukla]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Samal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shrivastava]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives,]]></article-title>
<source><![CDATA[International Immunopharmacology]]></source>
<year>2020</year>
<volume>85</volume>
</nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Merino]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticuerpos monoclonales: Aspectos básicos]]></article-title>
<source><![CDATA[Neurología]]></source>
<year>2011</year>
<volume>26</volume>
<page-range>301-6</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-Fernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz de Espada]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[César Milstein: 35 años de anticuerpos monoclonales]]></article-title>
<source><![CDATA[Inmunología]]></source>
<year>2011</year>
<volume>30</volume>
<page-range>30-3</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Casanova Estruch]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perfil de seguridad y aspectos prácticos a tener en cuenta en la administración de anticuerpos monoclonales]]></article-title>
<source><![CDATA[Neurología]]></source>
<year>2013</year>
<volume>28</volume>
<page-range>169-78</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gutiérrez Rodríguez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La Imunoterapia con Anticuerpos Monoclonales y sus Derivados,]]></article-title>
<source><![CDATA[Facultad de Medicina,]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Universidad de Cantabria, Santander, España ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández Baltazar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[González Christen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Conjugados Anticuerpo-Fármaco: El estado de arte]]></article-title>
<source><![CDATA[Revista Mexicana de Ciencias Farmacéuticas]]></source>
<year>2011</year>
<volume>42</volume>
<page-range>7</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[S. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Bagshawe]]></surname>
<given-names><![CDATA[K. D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibody Directed Enzyme Prodrug Therapy (ADEPT): Trials and tribulations]]></article-title>
<source><![CDATA[Advanced Drug Delivery Reviews]]></source>
<year>2017</year>
<volume>118</volume>
<page-range>2</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bermúdez Carvajal]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hidalgo Carrillo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mora Mata]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Mora]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ysmael-Acle Sánchez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mora Román]]></surname>
<given-names><![CDATA[J. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticuerpos Monoclonales Biespecíficos: Desarrollo, Producción y Uso como Terapia Anticancerígena]]></article-title>
<source><![CDATA[Revista Médica de la Universidad de Costa Rica]]></source>
<year>2019</year>
<volume>13</volume>
<page-range>11-29</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rincon-Silva]]></surname>
<given-names><![CDATA[N. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Jimenez-Vergara]]></surname>
<given-names><![CDATA[E. Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Rincon Silva]]></surname>
<given-names><![CDATA[J. D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunoterapia aplicada para el tratamiento de cáncer mediante vacunas desarrolladas con biomateriales]]></article-title>
<source><![CDATA[Revista Cubana de Química]]></source>
<year>2020</year>
<volume>32</volume>
<page-range>20-44</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vasquez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[de León]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Beltrán]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunoterapia en Cáncer: De los Inicios al Premio Nobel]]></article-title>
<source><![CDATA[Revista Peruana de Medicina Experimental y Salud Pública,]]></source>
<year>2020</year>
<volume>37</volume>
<page-range>115-21</page-range></nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current status and future directions of cancer immunotherapy,'']]></article-title>
<source><![CDATA[Journal of Cancer]]></source>
<year>2018</year>
<volume>9</volume>
<page-range>1773-81</page-range></nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Selby]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Engelhardt]]></surname>
<given-names><![CDATA[J. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Johnston]]></surname>
<given-names><![CDATA[R. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[L. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Thudium]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology]]></article-title>
<source><![CDATA[PLoS One,]]></source>
<year>2016</year>
<volume>11</volume>
<edition>e0161779,</edition>
</nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carreau]]></surname>
<given-names><![CDATA[N. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Pavlick]]></surname>
<given-names><![CDATA[A. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma]]></article-title>
<source><![CDATA[Future Oncology,]]></source>
<year>2019</year>
<volume>15</volume>
<page-range>349-58</page-range></nlm-citation>
</ref>
<ref id="B56">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Le]]></surname>
<given-names><![CDATA[D. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Lutz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Uram]]></surname>
<given-names><![CDATA[J. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Sugar]]></surname>
<given-names><![CDATA[E. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Onners]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Solt]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer]]></article-title>
<source><![CDATA[Journal of Immunotherapy]]></source>
<year>2013</year>
<volume>36</volume>
<page-range>382-9</page-range></nlm-citation>
</ref>
<ref id="B57">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arce Vargas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Furness]]></surname>
<given-names><![CDATA[A. J. S]]></given-names>
</name>
<name>
<surname><![CDATA[Litchfield]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenthal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ghorani]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies]]></article-title>
<source><![CDATA[Cancer Cell]]></source>
<year>2018</year>
<volume>33</volume>
<page-range>649-63</page-range></nlm-citation>
</ref>
<ref id="B58">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Reilly]]></surname>
<given-names><![CDATA[E. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[D. Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Dhani]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Renouf]]></surname>
<given-names><![CDATA[D. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial,]]></article-title>
<source><![CDATA[JAMA Oncology]]></source>
<year>2019</year>
<volume>5</volume>
<page-range>1431</page-range></nlm-citation>
</ref>
<ref id="B59">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu-Monette]]></surname>
<given-names><![CDATA[Z. Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[K. H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PD-1 expression and clinical PD-1 blockade in B-cell lymphomas]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2018</year>
<volume>131</volume>
<page-range>68-83</page-range></nlm-citation>
</ref>
<ref id="B60">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IFN-&#947; down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer]]></article-title>
<source><![CDATA[BMC Cancer]]></source>
<year>2019</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B61">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kwok]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Yau]]></surname>
<given-names><![CDATA[T. C. C]]></given-names>
</name>
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[J. W]]></given-names>
</name>
<name>
<surname><![CDATA[Tse]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kwong]]></surname>
<given-names><![CDATA[Y. L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pembrolizumab (Keytruda]]></article-title>
<source><![CDATA[Human Vaccines &amp; Immunotherapeutics]]></source>
<year>2016</year>
<volume>12</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2777-89</page-range></nlm-citation>
</ref>
<ref id="B62">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inman]]></surname>
<given-names><![CDATA[B. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Longo]]></surname>
<given-names><![CDATA[T. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ramalingam]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[M. R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer]]></article-title>
<source><![CDATA[Clinical Cancer Research]]></source>
<year>2017</year>
<volume>23</volume>
<page-range>1886-90</page-range></nlm-citation>
</ref>
<ref id="B63">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Venkatesulu]]></surname>
<given-names><![CDATA[B. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Hsieh]]></surname>
<given-names><![CDATA[C. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Sanders]]></surname>
<given-names><![CDATA[K. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Krishnan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent advances in radiation therapy of pancreatic cancer]]></article-title>
<source><![CDATA[F1000Research]]></source>
<year>2018</year>
<volume>7</volume>
<numero>F1000</numero>
<issue>F1000</issue>
<page-range>1931</page-range></nlm-citation>
</ref>
<ref id="B64">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rutz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ouyang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regulation of Interleukin-10 Expression]]></article-title>
<source><![CDATA[in Regulation of Cytokine Gene Expression in Immunity and Diseases]]></source>
<year>2016</year>
<page-range>89-116</page-range></nlm-citation>
</ref>
<ref id="B65">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caja]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dituri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mancarella]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Caballero-Diaz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Moustakas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Giannelli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TGF-&#946; and the Tissue Microenvironment: Relevance in Fibrosis and Cancer]]></article-title>
<source><![CDATA[International Journal of Molecular Science]]></source>
<year>2018</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B66">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jadidi-Niaragh]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential of CD73 as a target for cancer immunotherapy]]></article-title>
<source><![CDATA[Immunotherapy]]></source>
<year>2019</year>
<volume>11</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1353-5</page-range></nlm-citation>
</ref>
<ref id="B67">
<nlm-citation citation-type="">
<collab>Creative Biolabs</collab>
<source><![CDATA[Oleclumab Overview]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B68">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fossati]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Buzzonetti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Monego]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Catzola]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Scambia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fattorossi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM × anti-CD3),]]></article-title>
<source><![CDATA[Gynecologic Oncology]]></source>
<year>2015</year>
<volume>138</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>343-51</page-range></nlm-citation>
</ref>
<ref id="B69">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ströhlein]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Lordick]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ruttinger]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Grutzner]]></surname>
<given-names><![CDATA[K. U.]]></given-names>
</name>
<name>
<surname><![CDATA[Schemanski]]></surname>
<given-names><![CDATA[O. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Jäger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunotherapy of Peritoneal Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An OpenLabel, Multicenter, Phase I/II Trial]]></article-title>
<source><![CDATA[Onkologie]]></source>
<year>2011</year>
<volume>34</volume>
<page-range>101</page-range></nlm-citation>
</ref>
<ref id="B70">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seimetz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lindhofer]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bokemeyer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy]]></article-title>
<source><![CDATA[Cancer Treatment Reviews]]></source>
<year>2010</year>
<volume>36</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>458-67</page-range></nlm-citation>
</ref>
<ref id="B71">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dickinson]]></surname>
<given-names><![CDATA[K. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Price]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wanat]]></surname>
<given-names><![CDATA[K. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Swick]]></surname>
<given-names><![CDATA[B. L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dermal elastolysis in the setting of combination immunotherapy]]></article-title>
<source><![CDATA[Journal of Cutaneous Pathology]]></source>
<year>2019</year>
<volume>46</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>684-7</page-range></nlm-citation>
</ref>
<ref id="B72">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Opdivo, cabiralizumab combo falls short in pancreatic cancer]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B73">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Berlin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cardin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Harnessing the Immune System in Pancreatic Cancer,]]></article-title>
<source><![CDATA[Current Treatment Options in Oncology]]></source>
<year>2018</year>
<volume>19</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>48</page-range></nlm-citation>
</ref>
<ref id="B74">
<nlm-citation citation-type="">
<collab>U. S. National Library of Medicine</collab>
<source><![CDATA[Clinical Trials]]></source>
<year>2020</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
